Evaluating Women’s Preferences for Hepatitis C Treatment During Pregnancy

Tatyana Kushner, Jennifer Cohen, Phyllis C. Tien, Norah A. Terrault – 1 October 2018 – There is a rising prevalence of hepatitis C (HCV) among women of child‐bearing age nationally, which prompted a recommendation by national guidelines to screen all women for HCV during pregnancy. Women with HCV during pregnancy are at risk of perinatal transmission of HCV. Directly acting antiviral (DAA) therapy during pregnancy can potentially reduce the risk of perinatal transmission as well as cure women while they are engaged in antenatal care.

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development

Shogo Takahashi, Naoki Tanaka, Tatsuki Fukami, Cen Xie, Tomoki Yagai, Donghwan Kim, Thomas J. Velenosi, Tingting Yan, Kristopher W. Krausz, Moshe Levi, Frank J. Gonzalez – 1 October 2018 – Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and an association between altered bile acid (BA) metabolism, down‐regulation of farnesoid X receptor (FXR), which is a master regulator of BA metabolism, and hepatocarcinogenesis has been documented.

Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome

Dagmar Kollmann, Nicolas Goldaracena, Gonzalo Sapisochin, Ivan Linares, Nazia Selzner, Bettina E. Hansen, Mamatha Bhat, Mark S. Cattral, Paul D. Greig, Les Lilly, Ian D. McGilvray, Anand Ghanekar, David R. Grant, Markus Selzner – 28 September 2018 – The outcome after living donor liver transplantation (LDLT) using grafts with multiple bile ducts (BDs) remains unclear. We analyzed 510 patients who received an adult‐to‐adult right lobe LDLT between 2000 and 2015 and compared outcome parameters of those receiving grafts with 2 BDs (n = 169) with patients receiving grafts with 1 BD (n = 320).

Lymphoid Enhancer Factor 1 Contributes to Hepatocellular Carcinoma Progression Through Transcriptional Regulation of Epithelial‐Mesenchymal Transition Regulators and Stemness Genes

Chih‐Li Chen, Yu‐Shuen Tsai, Yen‐Hua Huang, Yuh‐Jin Liang, Ya‐Yun Sun, Chien‐Wei Su, Gar‐Yang Chau, Yi‐Chen Yeh, Yung‐Sheng Chang, Jui‐Ting Hu, Jaw‐Ching Wu – 28 September 2018 – Lymphoid enhancer factor 1 (LEF1) activity is associated with progression of several types of cancers. The role of LEF1 in progression of hepatocellular carcinoma (HCC) remains poorly known.

Multitarget Direct‐Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus

Shikha Shrivastava, Manasa Bhatta, Haley Ward, Sara Romani, Rebecca Lee, Elana Rosenthal, Anu Osinusi, Anita Kohli, Henry Masur, Shyam Kottilil, Eleanor Wilson – 27 September 2018 – Patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) have higher levels of immune activation, impaired antigen‐specific responses, and accelerated fibrogenesis compared to patients monoinfected with HCV. Whether different direct‐acting antiviral (DAA) combinations have differential effects on immunophenotypes and functions following successful HCV therapy remain unknown.

Subscribe to